Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Inc. engages in the provision of its own and operated community health centers. The company is headquartered in Tampa, Florida and currently employs 1 full-time employees. The company went IPO on 2001-06-21. The firm is primarily engaged in the discovery and development of products and services to improve people’s health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as nanobacteria. Its research is directed toward establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease. Nanobac’s drug discovery and development is focused on new and existing compounds that inhibit, destroy or neutralize CNPs. Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products (blood and tissue tests) include assays, antibodies and reagents for recognizing CNPs.